Skip to main
CDNA

CareDx (CDNA) Stock Forecast & Price Target

CareDx (CDNA) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 17%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

CareDx Inc demonstrated strong financial growth, achieving a 25% increase in top-line revenue in Q4, supported by a 17% increase in volume and a 5% rise in average selling prices (ASPs), alongside record revenues from patient and digital solutions. The company's fundamentals remain positive, with a 21% revenue growth in Q3, driven by a 13% increase in volume and reiteration of effective cash collection strategies, marking its highest cash collections in history in October. Future revenue projections have been adjusted upward, with estimates for 2026 raised to $433 million and for 2027 to $485 million, reflecting anticipated high return on investment and successful expansion of its sales force to drive further volume growth.

Bears say

CareDx Inc. has projected a negative revenue impact of $7.5 million for 2026, stemming from anticipated changes in Medicare reimbursement policies that may affect 4-8% of its business. Despite a 13% year-over-year growth in Q3'25 testing volumes, overall revenue growth remains sluggish, and the company faces challenges in successfully commercializing new diagnostic solutions, which are critical for its expansion. Additionally, with shares trading at 1.4 to 1.7 times projected revenue estimates for 2026—significantly lower than historical averages—investors are increasingly concerned about the company’s ability to navigate management changes and the competitive diagnostics landscape.

CareDx (CDNA) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 17% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CareDx (CDNA) Forecast

Analysts have given CareDx (CDNA) a Buy based on their latest research and market trends.

According to 6 analysts, CareDx (CDNA) has a Buy consensus rating as of Mar 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CareDx (CDNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.